Should genomic profiles be used routinely to determine which breast cancer patients receive adjuvant chemotherapy
Latest Conference Articles
Personalized treatment in oncology is a popular concept these days, but the goal remains elusive
Advertisement
It is time to rethink the way oncologists in the United States are treating ductal carcinoma in situ
The addition of sorafenib to capecitabine as a first-line therapy for patients with advanced breast cancer
Daniel A. Osman, MD, Founder and Course Director of the Miami Breast Cancer Conference Discusses Methods for Detecting Malignant Conditions in Breast Cancer
The climate for medical malpractice litigation in breast cancer treatment seems to be worsening
Advertisement
Breast pain is among the most common reasons that women seek medical attention from a breast specialist.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5